{"entity":{"id":"paper-anbl0531-twist-jco-2019","kind":"paper","name":"ANBL0531: response- and biology-based therapy for intermediate-risk neuroblastoma","aka":[],"tldr":"Further reducing chemotherapy according to biology and response, including observation alone for some infants, maintained a three-year survival of 96 percent in intermediate-risk neuroblastoma.","summary":"Children's Oncology Group phase 3 study of 404 children with intermediate-risk neuroblastoma treated with two, four or eight cycles of chemotherapy depending on stage, age, biology and response, with some subgroups receiving surgery alone.\n\nThree-year event-free survival was 83.2 percent and overall survival 94.9 percent; 12q loss and 1p loss identified patients with more events, and reduced therapy was successful in most subgroups.","asOf":"2026-09-17","links":[{"label":"J Clin Oncol 2019","url":"https://doi.org/10.1200/JCO.19.00919"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/31386611/"}],"tags":[],"related":[],"cancers":["neuroblastoma-intermediate-risk"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["jco"],"dependsOn":[],"notes":[],"journal":"Journal of Clinical Oncology","year":2019,"doi":"10.1200/JCO.19.00919","pmid":"31386611","authors":"Twist CJ, Schmidt ML, Naranjo A, et al.","paperType":"observational","findings":["Three-year overall survival 94.9 percent; event-free survival 83.2 percent.","Reduced therapy safe in favourable biology subgroups."],"whatItMeans":"Current intermediate-risk neuroblastoma protocols minimise chemotherapy to two to eight cycles by response and biology, following this study.","caveats":["Some subgroups with unfavourable biology had lower event-free survival, prompting refinements."],"changedPractice":true,"participants":404},"route":"/key-papers/paper-anbl0531-twist-jco-2019/","neighbours":{"cancer":[{"id":"neuroblastoma-intermediate-risk","kind":"cancer","name":"Intermediate-risk neuroblastoma","route":"/cancers/neuroblastoma-intermediate-risk/"}],"journal":[{"id":"jco","kind":"journal","name":"Journal of Clinical Oncology","route":"/journals/jco/"}]}}